Indivina

Medroxyprogesterone acetate, the active ingredient in Indivina, is a combined estrogen and progestogen presented as an oral tablet for oral use. It is employed in hormone replacement therapy to alleviate menopausal symptoms and support estrogen‑progestogen balance in women. GNH USA supplies Indivina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Indivina is a combined estrogen‑progestogen medication used in hormone replacement therapy for menopausal and postmenopausal conditions. - Menopausal vasomotor symptoms: reduces frequency and severity of hot flashes and night sweats. - Postmenopausal osteoporosis prevention: helps maintain bone mineral density and reduces fracture risk. - Estrogen deficiency after surgical menopause: restores hormonal balance in women with an intact uterus.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: swelling or discomfort. - Headache: transient tension‑type pain. - Bloating: abdominal fullness or mild edema. - Weight gain: modest increase in body weight. - Mood changes: irritability or mild depression.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Stroke or transient ischemic attack. - Myocardial infarction: heart attack risk. - Liver dysfunction: abnormal liver enzymes or hepatitis. - Gallbladder disease: biliary colic or cholelithiasis. - Breast cancer risk: increased incidence with long‑term use.

Before initiating therapy, evaluate patient history and risk factors. - Cardiovascular assessment: screen for hypertension, clotting disorders, or prior thromboembolic events. - Liver function: monitor hepatic enzymes in patients with liver disease. - Cancer history: avoid in women with estrogen‑dependent tumors. - Bone health: consider baseline bone mineral density testing. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Indivina may interact with several medicines that affect coagulation, hormone metabolism, or blood pressure. Major Interactions (Avoid): - Combined oral contraceptives: increased risk of venous thrombosis. - Anticoagulants (warfarin, DOACs): altered anticoagulant effect, requiring close monitoring. - Strong CYP3A4 inhibitors (ketoconazole, itraconazole): raise hormone concentrations and may increase adverse events.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine): reduce hormone levels, potentially diminishing efficacy. - Antihypertensives (ACE inhibitors, diuretics): may require blood pressure adjustments due to fluid retention.